vTv Therapeutics Presents Baseline Characteristics of the Enrolled Subjects in the Elevage Study Suggesting Comparability to the Post-Hoc Diabetes Subgroup of the Phase 3 STEADFAST Study
04 nov. 2020 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of...
Syneos Health to Present at Upcoming Investor Conferences
02 nov. 2020 17h20 HE
|
Syneos Health, Inc.
MORRISVILLE, N.C., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization)...
Innovation Pharmaceuticals Receives Pre-IND Response from FDA on COVID-19 Trial
02 nov. 2020 09h25 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today receipt of written feedback...
Innovation Pharmaceuticals and George Mason University Announce Public Release of Laboratory Testing Results Demonstrating Brilacidin’s COVID-19 Treatment Potential
30 oct. 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
Preprint article details research conducted at George Mason’s Regional Biocontainment Laboratory: Brilacidin shown in vitro to potently inhibit SARS-CoV-2, the novel coronavirus causing...
Euro-Australian collaboration offers scalable solutions for biotech: announced at Bio-Europe 2020
30 oct. 2020 06h00 HE
|
Cromos Pharma; Avance Clinical
DUBLIN, Ireland and ADELAIDE, Australia, Oct. 30, 2020 (GLOBE NEWSWIRE) -- Two dominant regional contract research organizations (CRO), Avance Clinical and Cromos Pharma, with operations in...
vTv Therapeutics to Present Study Update and Preliminary Data on Baseline Characteristics of Study Participants in Phase 2 Elevage Study Evaluating Azeliragon at 13th Clinical Trials on Alzheimer’s Disease (CTAD) Digital Event
29 oct. 2020 07h30 HE
|
vTv Therapeutics Inc.
HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer’s Disease...
BetterLife Provides Important Update on its Australian Clinical Study Design
28 oct. 2020 08h00 HE
|
BetterLife Pharma
Vancouver, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BetterLife Pharma (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company preparing human clinical trials of AP-003, its interferon alpha 2b...
Insights on the Tumor Infiltrating Lymphocytes Immunotherapy Global Market to 2025
28 oct. 2020 05h18 HE
|
Research and Markets
Dublin, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The "Global Tumor Infiltrating Lymphocytes Immunotherapy Market Opportunity & Clinical Trials Insight 2025" report has been added to...
Novavax Provides Phase 3 COVID-19 Vaccine Clinical Development Update
27 oct. 2020 09h03 HE
|
Novavax, Inc.
5,500 volunteers enrolled to date in pivotal Phase 3 clinical trial in the U.K. Study expanded to 15,000 participantsFull enrollment expected by end of NovemberEvent-driven interim data expected as...
BetterLife CEO Highlights Crucial Difference Between the Company’s Interferon Alpha 2b and Other Treatements
27 oct. 2020 07h30 HE
|
BetterLife Pharma
New York City, Oct. 27, 2020 (GLOBE NEWSWIRE) -- The Chief Executive Officer for BetterLife Pharma Inc. (OTCQB:BETRF) (CSE:BETR), an emerging biotechnology company currently preparing for clinical...